ArticleBMC cardiovascular disorders2026
Advanced prediction of cardiovascular-kidney-metabolic syndrome using eight machine learning models and 24 composite indices.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThis study aimed to construct and validate a machine learning classifier for cross-sectionally stratifying existing cardiovascular-kidney-metabolic (CKM) syndrome stages using routine composite inflammatory, metabolic and anthropometric indices, and to interpret core driving biomarkers via SHAP analysis. METHODS AND
resultsWe analyzed data from 12,106 participants from the National Health and Nutrition Examination Survey (NHANES). Among 24 initial biomarkers, 10 were selected after addressing multicollinearity and applying feature selection. Several machine learning algorithms were evaluated, with the LightGBM model demonstrating the highest performance (ROC AUC: 0.88). External validation using the China Health and Retirement Longitudinal Study (CHARLS) dataset confirmed the model's generalizability (ROC AUC: 0.84). SHapley Additive exPlanations (SHAP) analysis revealed that metabolic markers-specifically eGDR, METS_VF, TyG, and TyG_BMI-were consistently the strongest predictors across CKM stages, whereas inflammatory indicators showed more limited utility.
conclusionKey metabolic composite indices exhibit significant associations with CKM staging and may serve as practical, clinically feasible tools for risk stratification. The model's robust performance across distinct populations (U.S. and China) supports its potential clinical utility. Further validation in diverse populations and prospective studies is needed to confirm their predictive value and translational potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.